José Baselga, M.D., Ph.D.
Director & Chairman of Scientific Advisors
Jose Baselga is Physician-in-Chief at Memorial Sloan Kettering Cancer Center and a Professor of Medicine at Harvard Medical School. His research interests are in clinical breast cancer and in translational and early clinical research. He conducted the initial clinical trials of the monoclonal antibodies cetuximab and trastuzumab and is leading the clinical development of several new agents, including pertuzumab and PI3K inhibitors. He was previously the Chairman of the Medical Oncology Service and Founding Director of the recently established Vall d’Hebron Institute of Oncology (VHIO) at the Vall d’Hebron University Hospital in Barcelona. Jose completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York and subsequently stayed on as a faculty member of the Breast Medicine Service at Memorial Sloan-Kettering. Jose received his M.D. and Ph.D. from the Universidad Autonoma of Barcelona.
Jose is a member of the AACR board of directors, a member of the scientific advisory committee of the Ludwig Institute for Cancer Research, the immediate past President of ESMO and a past member of the board of directors of ASCO. He is a member of the editorial boards of Cancer Cell, Clinical Cancer Research and Annals of Oncology, and he is the funding Editor-in-Chief of the new flagship journal, Cancer Discovery.